Report two-year data from the pivotal PULSAR trial of aflibercept 8 mg in wet AMD
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2023
- Due
- 30 Sep 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The two-year data from the pivotal PULSAR trial for aflibercept 8 mg in wet AMD continue to be expected in the third quarter of 2023.”
What we found
Evidence strength A What the grades mean
Later filings state that top-line two-year PULSAR data for aflibercept 8 mg in wet AMD were announced in August 2023, before the end of the third quarter.
-
A Regeneron Pharmaceuticals 10-Q filed 2023-11-02
“In June 2023 and August 2023, the Company announced top-line, two-year (96 weeks) data for EYLEA HD from the pivotal PHOTON trial in patients with DME and the pivotal PULSAR trial in patients with wAMD, respectively.” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-K filed 2024-02-05
“In June 2023 and August 2023, the Company announced top-line, two-year (96 weeks) data for EYLEA HD from the pivotal PHOTON trial in patients with DME and the pivotal PULSAR trial in patients with wAMD, respectively.” ✓ confirmed on the page
Market reaction: the shares moved +2.1% against the S&P 500 over the three sessions around the disclosure (1 Nov 2023 to 6 Nov 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Two-year PULSAR trial data for aflibercept 8 mg
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REGN-006344 · Corrections policy